-
Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes Leukemia (IF 12.8) Pub Date : 2024-07-20 Johann-Christoph Jann, Christopher B. Hergott, Marisa Winkler, Yiwen Liu, Benjamin Braun, Anne Charles, Kevin M. Copson, Shougat Barua, Manja Meggendorfer, Niroshan Nadarajah, Shai Shimony, Eric S. Winer, Martha Wadleigh, Richard M. Stone, Daniel J. DeAngelo, Jacqueline S. Garcia, Torsten Haferlach, R. Coleman Lindsley, Marlise R. Luskin, Maximilian Stahl, Zuzana Tothova
-
Silencing GNAS enhances HDAC3i efficacy in CREBBP wild type B cell lymphoma Leukemia (IF 12.8) Pub Date : 2024-07-19 Patrizia Mondello
-
Nudt15-mediated inflammatory signaling contributes to divergent outcomes in leukemogenesis and hematopoiesis Leukemia (IF 12.8) Pub Date : 2024-07-18 Jiachen Wang, Yu Zhang, Lei Li, Liujiao Wang, Shuainan Sun, Bowu Wang, Yanwen Ge, Zhonghui Zhang
-
Clinical and molecular characteristics of extramedullary acute myeloid leukemias Leukemia (IF 12.8) Pub Date : 2024-07-18 Tariq Kewan, Waled S. Bahaj, Carmelo Gurnari, Olisaemeka D. Ogbue, Sudipto Mukherjee, Anjali Advani, James R. Cook, Heesun J. Rogers, Hetty E. Carraway, Suresh K. Balasubramanian, Valeria Visconte, Jaroslaw P. Maciejewski
-
Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis Leukemia (IF 12.8) Pub Date : 2024-07-18 Daniele Capitanio, Francesca R. Calledda, Vittorio Abbonante, Daniele Cattaneo, Manuela Moriggi, Bartalucci Niccolò, Cristina Bucelli, Delfina Tosi, Umberto Gianelli, Alessandro Maria Vannucchi, Alessandra Iurlo, Cecilia Gelfi, Alessandra Balduini, Alessandro Malara
-
Immunofluorescence microscopy on the blood smear identifies patients with myeloproliferative neoplasms Leukemia (IF 12.8) Pub Date : 2024-07-17 Carlo Zaninetti, Leonard Vater, Lars Kaderali, Carl C. Crodel, Tina M. Schnöder, Jessica Fuhrmann, Leonard Swensson, Jan Wesche, Carmen Freyer, Andreas Greinacher, Florian H. Heidel
-
Lipid-based nanosystems: the next generation of cancer immune therapy J. Hematol. Oncol. (IF 29.5) Pub Date : 2024-07-19 Ziyun Cheng, Seth-Frerich Fobian, Elena Gurrieri, Mohamadreza Amin, Vito Giuseppe D’Agostino, Mojtaba Falahati, Sara Zalba, Reno Debets, María J. Garrido, Mesha Saeed, Ann L. B. Seynhaeve, Hayri E. Balcioglu, Timo L. M. ten Hagen
Immunotherapy has become an important part of the oncotherapy arsenal. Its applicability in various cancer types is impressive, as well as its use of endogenous mechanisms to achieve desired ends. However, off-target or on-target-off-tumor toxicity, limited activity, lack of control in combination treatments and, especially for solid tumors, low local accumulation, have collectively limited clinical
-
Menin inhibitors for acute myeloid leukemia: latest updates from the 2023 ASH Annual Meeting J. Hematol. Oncol. (IF 29.5) Pub Date : 2024-07-19 Zhuo-Yu An, Xiao-Hui Zhang
Recent developments in menin inhibitors for relapsed or refractory acute myeloid leukemia (AML) were highlighted at the 2023 ASH Annual Meeting. Notably, revumenib showed promising efficacy, achieving a 100% ORR when combined with decitabine/cedazuridine and venetoclax. These findings underscore the potential of menin inhibitors in transforming AML treatment, particularly in genetically defined subgroups
-
Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features Blood Cancer J. (IF 12.9) Pub Date : 2024-07-19 Mihir D. Wechalekar, Lin-Pierre Zhao, Monika M. Kutyna, Lih En Hong, Joule Li, Kevin Hung, Hamish S. Scott, Anna Brown, Christopher C. Hahn, Karin Kassahn, Dariusz Ladon, David T. Yeung, Daniel Thomas, Mrinal Patnaik, Susanna Proudman, Lionel Ades, Mithun V. Shah, Chung H. Kok, Devendra K. Hiwase
-
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma Blood Cancer J. (IF 12.9) Pub Date : 2024-07-19 Bachisio Ziccheddu, Claudia Giannotta, Mattia D’Agostino, Giuseppe Bertuglia, Elona Saraci, Stefania Oliva, Elisa Genuardi, Marios Papadimitriou, Benjamin Diamond, Paolo Corradini, David Coffey, Ola Landgren, Niccolò Bolli, Benedetto Bruno, Mario Boccadoro, Massimo Massaia, Francesco Maura, Alessandra Larocca
-
A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria Am. J. Hematol. (IF 10.1) Pub Date : 2024-07-18 David J. Young
In this issue, the COMMODORE 11 and COMMODORE 22 trials of crovalimab for previously treated and treatment-naïve paroxysmal nocturnal hemoglobinuria, respectively, are presented, demonstrating efficacy and safety for both patient populations in comparison with the benchmark, eculizumab. Paroxysmal nocturnal hemoglobinuria (PNH) is a hemolytic anemia characterized by sometimes painful intravascular
-
Risk of myeloproliferative neoplasms among U.S. Veterans from Korean, Vietnam, and Persian Gulf War eras Am. J. Hematol. (IF 10.1) Pub Date : 2024-07-18 Andrew Tiu, Zoe McKinnell, Shanshan Liu, Puneet Gill, Martha Antonio, Zoe Shancer, Nandan Srinivasa, Guoqing Diao, Ramesh Subrahmanyam, Craig M. Kessler, Maneesh Jain
The Promise to Address Comprehensive Toxics (PACT) Act expanded U.S. Veterans' health care and benefits for conditions linked to service‐connected exposures (e.g., Burn Pits, Agent Orange). However, myeloproliferative neoplasms (MPN) are not recognized as presumptive conditions for Veterans exposed to these toxic substances. This study evaluated the development of MPN among U.S. Veterans from the Korean
-
Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma. Haematologica (IF 8.2) Pub Date : 2024-07-18 Tamer Othman, Paul Frankel, Pamela Allen, Leslie L Popplewell, Geoffrey Shouse, Tanya Siddiqi, Alexey V Danilov, Nora Ruel, Shari Daniels, Lacolle Peters, Stella Khoo, Steven T Rosen, Elad Sharon, Miguel Villalona-Calero, Christopher Ruel, Joseph Tuscano, Alex F Herrera
Patients with relapsed/refractory (R/R) transformed diffuse large B-cell lymphoma (DLBCL) from indolent B-cell lymphomas, including Richter transformation (RT), have a poor prognosis. PD-1/PD-L1 antibodies produce modest objective and complete response rates (ORR and CRR) in B-NHL as monotherapy but may synergize with immunogenic chemotherapies like gemcitabine and oxaliplatin (GemOx). Thus, we evaluated
-
A targeted gene signature stratifying mediastinal gray zone lymphoma into classical HL-like or PMBL-like subtypes. Haematologica (IF 8.2) Pub Date : 2024-07-18 Grazia Gargano, Maria Carmela Vegliante, Flavia Esposito, Susanna A Pappagallo, Elena Sabattini, Claudio Agostinelli, Stefano A Pileri, Valentina Tabanelli, Maurilio Ponzoni, Luisa Lorenzi, Fabio Facchetti, Arianna Di Napoli, Marco Lucioni, Marco Paulli, Lorenzo Leoncini, Stefano Lazzi, Stefano Ascani, Giuseppina Opinto, Gian Maria Zaccaria, Giacomo Volpe, Paolo Mondelli, Antonella Bucci, Laura Selicato
Not available.
-
Risk of infections in multiple myeloma. A population-based study on 8672 multiple myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry. Haematologica (IF 8.2) Pub Date : 2024-07-18 Cecilie Hveding Blimark, Kristina Carlson, Christopher Day, Sigrun Einarsdottir, Gunnar Juliusson, Moshtak Karma, Dorota Knut-Bojanowska, Gunnar Larfors, Ingemar Turesson, Mariana Villegas-Scivetti, Ingigerdur Sverrisdóttir
In multiple myeloma (MM), advancements in treatments and toxicity management have enhanced survival rates. This, coupled with shifting age demographics in MM, necessitates an updated understanding of infection risks in MM patients compared to the general population. Using Swedish population-based registries, we investigated the incidence of infections in 8,672 Swedish symptomatic MM patients diagnosed
-
Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma. Haematologica (IF 8.2) Pub Date : 2024-07-18 Megan Melody, Leo I Gordon
Historically, management of relapsed or refractory (R/R) Diffuse large B-cell (DLBCL) following first-line chemoimmunotherapy has been second-line chemotherapy, followed by high-dose chemotherapy and consolidative autologous hematopoietic stem cell transplantation (auto-HSCT), resulting in durable remissions in approximately 40% of patients. In 2017, chimeric antigen receptor (CAR) T-cell therapy changed
-
No clear benefit of preventive cranial radiotherapy in childhood Philadelphia-positive acute lymphoblastic leukemia: a retrospective analysis of the EsPhALL2010 study. Haematologica (IF 8.2) Pub Date : 2024-07-18 Valentino Conter, Maria Grazia Valsecchi, Paola De Lorenzo, Virginie Gandemer, Mats Heyman, Vaskar Saha, Paulina Diaz, Chi-Kong Li, Andishe Attarbaschi, Gabriele Escherich, Jan Stary, Martin Schrappe, Rob Pieters, Gunnar Cario, Andrea Biondi
Not available.
-
Multiple myeloma in the young: insights on prognosis, clinical features and treatment outcome derived from nationwide German registry data and a nested multicenter sample. Haematologica (IF 8.2) Pub Date : 2024-07-18 Abdulaziz Kamili, Paymon Ahmadi, Lisa Leypoldt, Franziska Marquard, Christoph Schaefers, Ricardo Kosch, Frederik Peters, Henrik Kusche, Tanja Zamrik, Christine Hanoun, Maximilian Seib, Evgenii Shumilov, Theo Leitner, Cyrus Khandanpour, Carsten Bokemeyer, Katja Weisel, Susanne Ghandili
Not available.
-
Minimal residual disease assessment in transplant-eligible patients with multiple myeloma: real-world applications of multiparametric flow cytometry-DURAClone (CAREMM-2104). Haematologica (IF 8.2) Pub Date : 2024-07-18 Ari Ahn, Sung-Soo Park, Yonggoo Kim, Jung Yeon Lee, Jong-Mi Lee, Jin Jung, Myungshin Kim, Chang-Ki Min
Not available.
-
Mimicry of inherited red cell disorders: the result of somatic mutations in a clonal myeloid disease. Haematologica (IF 8.2) Pub Date : 2024-07-18 Marshall A Lichtman, Audrey N Jajosky
Not available.
-
A new frontier in the battle against infant acute lymphoblastic leukemia. Haematologica (IF 8.2) Pub Date : 2024-07-18 Daisuke Tomizawa
Not available.
-
Co-transfection of murine NXPE2 and murine glycophorin A confers reactivity with Ter-119. Haematologica (IF 8.2) Pub Date : 2024-07-18 Gregory R Keele, Ariel M Hay, Nadia K Holness, Arijita Jash, Sarah E Ewald, Callan O'Connor, Matthew Vincent, Monika Dzieciatkowska, Angelo D'Alessandro, Gary A Churchill, James C Zimring
Not available.
-
Polytypic B cells, monotypic/monoclonal B-cell proliferations, and neoplastic T cells diverge from TET2-/DNMT3A-mutant clonal hematopoiesis in follicular helper T-cell lymphomas. Haematologica (IF 8.2) Pub Date : 2024-07-18 Natasha E Lewis, Kseniya Petrova-Drus, Rohan Sardana, Sarah Huet, Qi Gao, Shenon Sethi, Chad Vanderbilt, Wenbin Xiao, Mikhail Roshal, Jeeyeon Baik, Himanshu Bhurtel, Alison J Moskowitz, Steven M Horwitz, Ahmet Dogan
Not available.
-
Reference interval of free light chains ratio in patients with end-stage renal disease on chronic hemodialysis. Haematologica (IF 8.2) Pub Date : 2024-07-18 Camila Peña, Ricardo Valjalo, Ramón Pérez, Marco Álvarez, Pablo Bustamante, Esteban Forray, Viviana Balboa, Alexis Bondi
Not available.
-
Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia – a FILO study Leukemia (IF 12.8) Pub Date : 2024-07-17 Corentin Orvain, Sarah Bertoli, Pierre Peterlin, Yohann Desbrosses, Pierre-Yves Dumas, Alexandre Iat, Marie-Anne Hospital, Martin Carre, Emmanuelle Tavernier, Jérémie Riou, Anne Bouvier, Audrey Bidet, Sylvie Tondeur, Florian Renosi, Marie-Joelle Mozziconacci, Pascale Flandrin-Gresta, Bérengère Dadone-Montaudié, Eric Delabesse, Arnaud Pigneux, Mathilde Hunault-Berger, Christian Recher
-
Validation of independent prognostic significance of blast count in a large cohort of MDS patients Leukemia (IF 12.8) Pub Date : 2024-07-16 Raniah Al Amri, Vandana Baloda, Sara A. Monaghan, Flavia G. Rosado, Erika M. Moore, Bryan Rea, Miroslav Djokic, Nidhi Aggarwal, Svetlana A. Yatsenko, Nathanael G. Bailey
-
Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia Am. J. Hematol. (IF 10.1) Pub Date : 2024-07-17 Sanam Loghavi, Qing Wei, Farhad Ravandi, Andres E. Quesada, Mark J. Routbort, Shimin Hu, Gokce A. Toruner, Sa A. Wang, Wei Wang, Roberto N. Miranda, Shaoying Li, Jie Xu, Courtney D. DiNardo, Naval Daver, Tapan M. Kadia, Ghayas C. Issa, Hagop M. Kantarjian, L. Jeffrey Medeiros, Guilin Tang
Cytogenomic characterization is crucial for the classification and risk stratification of acute myeloid leukemia (AML), thereby facilitating therapeutic decision‐making. We examined the clinical utility of optical genome mapping (OGM) in 159 AML patients (103 newly diagnosed and 56 refractory/relapsed), all of whom also underwent chromosomal banding analysis (CBA), fluorescence in situ hybridization
-
Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go? Am. J. Hematol. (IF 10.1) Pub Date : 2024-07-17 Jennifer Marvin‐Peek, Jason S. Gilbert, Daniel A. Pollyea, Courtney D. DiNardo
-
FBXL6 is a vulnerability in AML and unmasks proteolytic cleavage as a major experimental pitfall in myeloid cells Leukemia (IF 12.8) Pub Date : 2024-07-16 Anna Sperk, Antje Gabriel, Daniela Koch, Abirami Augsburger, Victoria Sanchez, David Brockelt, Rupert Öllinger, Thomas Engleitner, Piero Giansanti, Romina Ludwig, Priska Auf der Maur, Wencke Walter, Torsten Haferlach, Irmela Jeremias, Roland Rad, Barbara Steigenberger, Bernhard Kuster, Ruth Eichner, Florian Bassermann
-
Using Mendelian Randomisation to search for modifiable risk factors influencing the development of clonal haematopoiesis Blood Cancer J. (IF 12.9) Pub Date : 2024-07-16 Jessica M. Hislop, Molly Went, Charlie Mills, Amit Sud, Philip J. Law, Richard S. Houlston
-
Improved prevention and treatment strategies for differentiation syndrome contribute to reducing early mortality in patients with acute promyelocytic leukemia Blood Cancer J. (IF 12.9) Pub Date : 2024-07-15 Qian Wu, Xiaofei Yang, Jingren Zhang, Mengxing Xue, Xueqing Dou, Zheng Ge, Yifei Chen, Weiying Gu, Weimin Dong, Hongying Cao, Naike Jiang, Xuemei Sun, Zefa Liu, Jinning Shi, Hui Chen, Cixian Zhang, Fengling Min, Hongli Sun, Xiaoli Qian, Hongjian Yuan, Yuan Feng, De-Pei Wu, Suning Chen
-
PHF6 suppresses self-renewal of leukemic stem cells in AML Leukemia (IF 12.8) Pub Date : 2024-07-14 Sapana S. Jalnapurkar, Aishwarya S. Pawar, Subin S. George, Charles Antony, Patrick Somers, Jason Grana, Victoria K. Feist, Sandeep Gurbuxani, Vikram R. Paralkar
-
Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma Leukemia (IF 12.8) Pub Date : 2024-07-13 Udita Jindal, Mukesh Mamgain, Uttam Kumar Nath, Isha Sharma, Bhaskar Pant, Ankita Sharma, Archita Gupta, Khaliqur Rahman, Sunil Yadav, Manish Pratap Singh, Shaktiprasad Mishra, Chandra Praksah Chaturvedi, Jose Courty, Navin Singh, Seema Gupta, Sanjeev Kumar, Shailendra Prasad Verma, Saumyaranjan Mallick, Ajay Gogia, Sunil Raghav, Jayanta Sarkar, Kinshuk Raj Srivastava, Dipak Datta, Neeraj Jain
-
Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition Leukemia (IF 12.8) Pub Date : 2024-07-13 Sana Chaudhry, Felipe Beckedorff, Shaista Shabbir Jasdanwala, Tulasigeri M. Totiger, Maurizio Affer, Abimbola Eunice Lawal, Skye Montoya, Francesco Tamiro, Olivia Tonini, Alexandra Chirino, Andrew Adams, Anya K. Sondhi, Stephen Noudali, Alyssa Mauri Cornista, Miah Nicholls, Jumana Afaghani, Paola Robayo, Daniel Bilbao, Stephen D. Nimer, Jose Antonio Rodríguez, Shruti Bhatt, Eric Wang, Justin Taylor
-
Prognostic and therapeutic implications of TP53 expression in chronic myelomonocytic leukemia Blood Cancer J. (IF 12.9) Pub Date : 2024-07-12 Yu-Hung Wang, Chien-Chin Lin, Kristian Gurashi, Chi-Yuan Yao, Andres Jerez, Hsin-An Hou, Wen-Chien Chou, Hwei-Fang Tien, Kiran Batta, Daniel H. Wiseman
-
Correction to “Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma” Am. J. Hematol. (IF 10.1) Pub Date : 2024-07-12
Zanwar S, Ho M, Lin Y, Kapoor P, Binder M, Buadi FK, Dispenzieri A, Dingli D, Fonder A, Gertz MA, Gonsalves W, Hayman SR, Hwa Y, Hobbs M, Kourelis T, Lacy MQ, Leung N, Muchtar E, Warsame R, Jevremovic D, Kyle RA, Rajkumar SV, Kumar S. Am J Hematol. 2023 Oct;98(10):1540–1549. doi: 10.1002/ajh.27023. Epub 2023 Jul 8. PMID: 37421603. In this article, we forgot to acknowledge that the work was supported
-
Correction to “Risk factors for severe infection and mortality in patients with COVID‐19 in patients with multiple myeloma and AL amyloidosis” Am. J. Hematol. (IF 10.1) Pub Date : 2024-07-12
Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, Binder M, Chanan-Khan A, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves W, Go RS, Hayman S, Kapoor P, Kourelis T, Lacy MQ, Leung N, Lin Y, Muchtar E, Roy V, Sher T, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S. Am J Hematol. 2023 Jan;98(1):49–55. doi: 10.1002/ajh.26762. Epub 2022 Oct 24. PMID: 36226510. In
-
The RNA helicases DDX19A/B modulate selinexor sensitivity by regulating MCL1 mRNA nuclear export in leukemia cells Leukemia (IF 12.8) Pub Date : 2024-07-11 Tatsuya Terasaki, Yuichiro Semba, Kensuke Sasaki, Hiroshi Imanaga, Kiyoko Setoguchi, Takuji Yamauchi, Shigeki Hirabayashi, Fumihiko Nakao, Koshi Akahane, Takeshi Inukai, Takaomi Sanda, Koichi Akashi, Takahiro Maeda
-
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial Leukemia (IF 12.8) Pub Date : 2024-07-10 Fabio Efficace, Francois-Xavier Mahon, Johan Richter, Alfonso Piciocchi, Marta Cipriani, Franck E. Nicolini, Jiri Mayer, Daniela Zackova, Jeroen J. W. M. Janssen, Panayiotis Panayiotidis, Hanne Vestergaard, Perttu Koskenvesa, Antonio Almeida, Henrik Hjorth-Hansen, Joaquin Martinez-Lopez, Ulla Olsson-Strömberg, Andreas Hochhaus, Marc G. Berger, Gabriel Etienne, Hana Klamova, Edgar Faber, Philippe Rousselot
-
How complete must an AML remission be? Blood (IF 21.0) Pub Date : 2024-07-11 Christopher S. Hourigan
-
-
-
In cancer, not all platelets are created equal Blood (IF 21.0) Pub Date : 2024-07-11 Elisabeth M. Battinelli
-
-
Paving the way to factor X deficiency therapies Blood (IF 21.0) Pub Date : 2024-07-11 Jeremy P. Wood
-
-
Chronic eosinophilic leukemia with a novel JAK1 mutation responds well to the JAK1/2 inhibitor ruxolitinib Blood (IF 21.0) Pub Date : 2024-07-11 Qing Wei, Jie Xu
-
Mantle cell lymphoma with IRTA1+ reactive expansion of the marginal zone Blood (IF 21.0) Pub Date : 2024-07-11 Brunangelo Falini, Stefano Lazzi
-
Umbilical cord blood T cells can be isolated and enriched by CD62L selection for use in 'off the shelf' chimeric antigen receptor T-cell therapies to widen transplant options. Haematologica (IF 8.2) Pub Date : 2024-07-11 Christos Georgiadis, Lauren Nickolay, Farhatullah Syed, Hong Zhan, Soragia Athina Gkazi, Annie Etuk, Ulrike Abramowski-Mock, Roland Preece, Piotr Cuber, Stuart Adams, Giorgio Ottaviano, Waseem Qasim
Umbilical cord blood (UCB) T cells exhibit distinct naive ontogenetic profiles and may be an attractive source of starting cells for the production of chimeric antigen receptor (CAR) T cells. Pre-selection of UCB-T cells on the basis of CD62L expression was investigated as part of a machine-based manufacturing process, incorporating lentiviral transduction, CRISPR-Cas9 editing, T-cell expansion and
-
Germline variants in acquired aplastic anemia: current knowledge and future perspectives. Haematologica (IF 8.2) Pub Date : 2024-07-11 Peicheng Wang, Wanzhi Jiang, Tianyi Lai, Qi Liu, Yingying Shen, Baodong Ye, Dijiong Wu
Aplastic anemia (AA) is a disease characterized by hematopoiesis failure, bone marrow aplasia, and pancytopenia. It can be inherited or acquired. Although acquired AA is believed to be immune-mediated and random, new evidence suggests an underlying genetic predisposition. Besides confirmed genomic mutations that contribute to inherited AA (such as pathogenic mutations of TERT and TERC), germline variants
-
Combinatorial strategies targeting NEAT1 and AURKA as new potential therapeutic options for multiple myeloma. Haematologica (IF 8.2) Pub Date : 2024-07-11 Noemi Puccio, Gloria Manzotti, Elisabetta Mereu, Federica Torricelli, Domenica Ronchetti, Michela Cumerlato, Ilaria Craparotta, Laura Di Rito, Marco Bolis, Valentina Traini, Veronica Manicardi, Valentina Fragliasso, Yvan Torrente, Nicola Amodio, Niccolò Bolli, Elisa Taiana, Alessia Ciarrochi, Roberto Piva, Antonino Neri
Multiple myeloma (MM) is a dreadful disease, marked by the uncontrolled proliferation of clonal plasma cells (PCs) within the bone marrow (BM). MM is characterized by a highly heterogeneous clinical and molecular background, supported by severe genomic alterations. Important deregulation of long non-coding RNAs (lncRNAs) expression has been reported in MM patients, influencing progression and therapy
-
Excellent outcome of children/adolescents with primary mediastinal large B-cell lymphoma treated with FAB/LMB-based chemotherapy regimen with rituximab. Haematologica (IF 8.2) Pub Date : 2024-07-11 Marie Emilie Dourthe, Anne Auperin, Charlotte Rigaud, Melissa Barbati, Jacinthe Bonneau, Nimrod Buchbinder, Marie-Laure Couec, Peggy Dartigues, Stéphane Ducassou, Nathalie Garnier, Stéphanie Haouy, Bénédicte Jonca, Anne Jourdain, Amaury Leruste, Thierry Molina, Françoise Montravers, Marlène Pasquet, Aurélie Phulpin, Maryline Poirée, Mathieu Simonin, Alexandra Spiegel, Arnauld Verschuur, Thierry Leblanc
Not available.
-
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial. Haematologica (IF 8.2) Pub Date : 2024-07-11 Noemí Puig, Cristina Agulló, Teresa Contreras, José-Juan Pérez, Irene Aires, María-José Calasanz, Ramón García-Sanz, Sergio Castro, Joaquín Martínez-López, Paula Rodríguez-Otero, Verónica González-Calle, Marta S González, Albert Oriol, Norma C Gutiérrez, Rafael Ríos-Tamayo, Laura Rosiñol, Miguel-Ángel Álvarez, Joan Bargay, Ana-Pilar González-Rodríguez, Adrián Alegre, Fernando Escalante, María-Belén
The value of quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify the M-protein is being investigated in patients with monoclonal gammopathies but no data are yet available in high-risk smoldering myeloma (HRsMM). We have therefore investigated QIP-MS to monitor peripheral residual disease (PRD) in 62 HRsMM patients enrolled in the GEM-CESAR trial. After 24 cycles of maintenance
-
New precision medicine weapons for targeted treatment of high-risk B-cell precursor acute lymphoblastic leukemia. Haematologica (IF 8.2) Pub Date : 2024-07-11 Sinisa Dovat, Joseph Schramm
Not available.
-
Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes. Haematologica (IF 8.2) Pub Date : 2024-07-11 Ángel Serna, Víctor Navarro, Gloria Iacoboni, Laia López, Juan-Manuel Sancho, Eva González-Barca, Alberto López-García, Raúl Córdoba, Adolfo Sáez, Ana Jiménez Ubieto, Ainara Ferrero, Tomás García, Ángela Sánchez, Cristina García, Marc Bosch, Alba Cabirta, Moraima Jiménez, Ana Marín-Niebla, Francesc Bosch, Pau Abrisqueta
Not available.
-
Extending duration of letermovir prophylaxis in haploidentical stem cell transplantation. Haematologica (IF 8.2) Pub Date : 2024-07-11 Pongthep Vittayawacharin, Benjamin J Lee, Shawn Griffin, Jean Doh, Julie Smith, Hannah Nam, Emily Blodget, Deepa Jeyakumar, Piyanuch Kongtim, Stefan O Ciurea
Not available.
-
Microbiota signature of oral chronic graft-versus-host disease 6+ years after transplantation. Haematologica (IF 8.2) Pub Date : 2024-07-11 Armin Rashidi, Lang Liang, Ted Gooley, Philippe P Hujoel, Alex Zevin, Marilynn Rothen, Mary K Hagstrom, Corey Cutler, Stephanie J Lee, David R Dean, Hervé Y Sroussi, Nathaniel S Treister
Not available.
-
The Gordian knot: ruxolitinib or transplants for high-risk myelofibrosis. Haematologica (IF 8.2) Pub Date : 2024-07-11 Robert Peter Gale, Giovanni Barosi
Not available.
-
Have we truly uncovered the key to primary vitreoretinal lymphoma's pathway to the central nervous system? Haematologica (IF 8.2) Pub Date : 2024-07-11 Liang Wang
Not available.
-
Hemolytic versus malproductive anemia in large granular lymphocytic leukemia Leukemia (IF 12.8) Pub Date : 2024-07-09 Olisaemeka Ogbue, Tariq Kewan, Carlos Bravo-Perez, Serhan Unlu, Naomi Kawashima, Nakisha D. Williams, Arooj Ahmed, Luca Guarnera, Carmelo Gurnari, Valeria Visconte, Jaroslaw P. Maciejewski